Yoon-Koo Kang, Min-Hee Ryu, Yong Sang Hong, Chang-Min Choi, Tae Won Kim, Baek-Yeol Ryoo, Jeong Eun Kim, John R. Weis, Rachel Kingsford, Cheol Hee Park, Seong Jang, Arlo McGinn, Theresa L. Werner, Sunil Sharma
Cancer Res Treat. 2024;56(3):743-750. Published online January 18, 2024
Purpose This study aimed to report the results from an early-phase study of rivoceranib, an oral tyrosine kinase inhibitor highly selective for vascular endothelial growth factor receptor 2, in patients with advanced solid tumors.
Materials and Methods In this open-label, single-arm, dose-escalating, multicenter three-part phase 1/2a trial, patients had advanced solid tumors refractory to conventional therapy. Part 1 evaluated the safety and pharmacokinetics of five ascending once-daily doses of rivoceranib from 81 mg to 685 mg. Part 2 evaluated the safety and antitumor activity of once-daily rivoceranib 685 mg. Part 3 was conducted later, due to lack of maximum tolerated dose determination in part 1, to evaluate the safety and preliminary efficacy of once-daily rivoceranib 805 mg in patients with unresectable or advanced gastric cancer.
Results A total of 61 patients were enrolled in parts 1 (n=25), 2 (n=30), and 3 (n=6). In parts 1 and 2, patients were white (45.5%) or Asian (54.5%), and 65.6% were male. The most common grade ≥ 3 adverse events were hypertension (32.7%), hyponatremia (10.9%), and hypophosphatemia (10.9%). The objective response rate (ORR) was 15.2%. In part 3, dose-limiting toxicities occurred in two out of six patients: grade 3 febrile neutropenia decreased appetite, and fatigue. The ORR was 33%.
Conclusion The recommended phase 2 dose of rivoceranib was determined to be 685 mg once daily, which showed adequate efficacy with a manageable safety profile (NCT01497704 and NCT02711969).
Purpose
Pyrotinib is a newly-developed irreversible pan-ErbB receptor tyrosine kinase inhibitor. This study reported the first real-world data of pyrotinib-based therapy in metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC), focusing on efficacy in lapatinib-treated patients and in brain metastasis.
Materials and Methods
One hundred thirteen patients with metastatic HER2-positive BC treated with pyrotinib-based therapy in Fudan University Shanghai Cancer Center under non-clinical trial settings from September 1, 2018 to March 1, 2019 were included.
Results
Over half patients have received more than two lines of systematic therapy and exposed to two or more kinds of anti-HER2 agents. Most patients received a combined therapy, commonly of pyrotinib plus capecitabine, or vinorelbine or trastuzumab. Median progression-free survival (PFS) was 6.3 months (range, 5.54 to 7.06 months) and objective response rate (ORR) was 29.5%, with two patients (1.9%) achieving complete response. Lapatinib-naïve patients had significantly longer PFS than lapatinib-treated patients (9.0 months vs. 5.4 months, p=0.001). ORR for lapatinib-treated patients was 23.2%. Thirty-one of 113 patients have brain metastasis. Median PFS was 6.7 months and intracranial ORR was 28%. For patients without concurrent radiotherapy and/or brain surgery, the ORR was very low (6.3%). But for patients receiving concurrent radiotherapy and/or brain surgery, the ORR was 66.7%, and three patients achieved complete response. Most common adverse event was diarrhea.
Conclusion
Pyrotinib-based therapy demonstrated promising effects in metastatic HER2-positive BC and showed activity in lapatinib-treated patients. For patients with brain metastasis, pyrotinib-based regimen without radiotherapy showed limited efficacy, but when combined with radiotherapy it showed promising intracranial control.
Citations
Citations to this article as recorded by
Neurotoxicity-sparing radiotherapy for brain metastases in breast cancer: a narrative review Dagmara Buczek, Renata Zaucha, Jacek Jassem Frontiers in Oncology.2024;[Epub] CrossRef
Comparison of the prognostic effect of pyrotinib plus trastuzumab and chemotherapy different lines therapy in HER2-positive advanced breast cancer Yangqingqing Zhou, Hui Wang, Jiao Yang, Fan Wang, Danfeng Dong, Xiaoai Zhao, Le Wang, Ruiyuan He, Zhiping Ruan, Jin Yang Journal of Chemotherapy.2024; : 1. CrossRef
HER2-positive metastatic breast cancer with brain metastases responds favorably to pyrotinib and trastuzumab-based treatment: A case report and literature review Min-long Chen, Wenjie Yu, Binbin Cui, Yijian Yu, Zhaosheng Ma Frontiers in Oncology.2023;[Epub] CrossRef
Efficacy and safety of inetetamab-containing regimens in patients with HER2-positive metastatic breast cancer: a real-world retrospective study in China Xiaoyu Liu, Peng Zhang, Chao Li, Xiang Song, Zhaoyun Liu, Wenna Shao, Sumei Li, Xinzhao Wang, Zhiyong Yu Frontiers in Oncology.2023;[Epub] CrossRef
Evolving management of HER2+ breast cancer brain metastases and leptomeningeal disease Matthew N. Mills, Whitney King, Aixa Soyano, Yolanda Pina, Brian J. Czerniecki, Peter A. Forsyth, Hatem Soliman, Hyo S. Han, Kamran A. Ahmed Journal of Neuro-Oncology.2022; 157(2): 249. CrossRef
Temporal Heterogeneity of HER2 Expression and Spatial Heterogeneity of 18F-FDG Uptake Predicts Treatment Outcome of Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer Chengcheng Gong, Cheng Liu, Zhonghua Tao, Jian Zhang, Leiping Wang, Jun Cao, Yannan Zhao, Yizhao Xie, Xichun Hu, Zhongyi Yang, Biyun Wang Cancers.2022; 14(16): 3973. CrossRef
Cost-Effectiveness of Pyrotinib Plus Capecitabine versus Lapatinib Plus Capecitabine for the Treatment of HER2-Positive Metastatic Breast Cancer in China: A Scenario Analysis of Health Insurance Coverage Yuwen Bao, Zhuolin Zhang, Xuan He, Lele Cai, Xiao Wang, Xin Li Current Oncology.2022; 29(9): 6053. CrossRef
An Insight into Molecular Targets of Breast Cancer Brain Metastasis Mohammed Kaleem, Mahmood Hassan Dalhat, Lubna Azmi, Turky Omar Asar, Wasim Ahmad, Maimonah Alghanmi, Amal Almostadi, Torki A. Zughaibi, Shams Tabrez International Journal of Molecular Sciences.2022; 23(19): 11687. CrossRef
Real-World Outcome and Prognostic Factors Among HER2-Positive Metastatic Breast Cancer Patients Receiving Pyrotinib-Based Therapy: A Multicenter Retrospective Analysis Jing Liu, Xianglu Sun, Qianyu Du, Jinghao Yao, Mengfen Dai, Qianqian Cheng, Han Xu, Yawei Li, Xiuli Liu, Mingliang Zhang, Yongchun Zhou, Yan Yang Breast Cancer: Targets and Therapy.2022; Volume 14: 491. CrossRef
Eribulin Efficacy on Brain Metastases in Heavily Pretreated Patients with Metastatic Breast Cancer Renaud Sabatier, Johan Martin, Cécile Vicier, Mathilde Guérin, Audrey Monneur, Magali Provansal, Louis Tassy, Carole Tarpin, Jean-Marc Extra, Frédéric Viret, Anthony Goncalves Journal of Clinical Medicine.2021; 10(6): 1272. CrossRef
Pyrotinib Combined With Vinorelbine in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study Yi Li, Yixuan Qiu, Huihui Li, Ting Luo, Wei Li, Hong Wang, Bin Shao, Biyun Wang, Rui Ge Frontiers in Oncology.2021;[Epub] CrossRef
Multiple Administrations of Itraconazole Increase Plasma Exposure to Pyrotinib in Chinese Healthy Adults Yueyue Liu, Qian Zhang, Chao Lu, Wei Hu Drug Design, Development and Therapy.2021; Volume 15: 2485. CrossRef
Brain Metastases in HER2-Positive Breast Cancer: Current and Novel Treatment Strategies Alejandro Garcia-Alvarez, Andri Papakonstantinou, Mafalda Oliveira Cancers.2021; 13(12): 2927. CrossRef
Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine in Patients With Previously Treated HER2-Positive Metastatic Breast Cancer: A Multicenter, Retrospective Study Yizhao Xie, Yi Li, Luo Ting, Die Sang, Peng Yuan, Wei Li, Huihui Li, Rui Ge, Biyun Wang Frontiers in Oncology.2021;[Epub] CrossRef
The Efficacy of Pyrotinib as a Third- or Higher-Line Treatment in HER2-Positive Metastatic Breast Cancer Patients Exposed to Lapatinib Compared to Lapatinib-Naive Patients: A Real-World Study D. J Ouyang, Q. T Chen, M. Anwar, N. Xie, Q. C. Ouyang, P. Z. Fan, L. Y. Qian, G. N. Chen, E. X. Zhou, L. Guo, X. W. Gu, B. N. Ding, X. H. Yang, L. P. Liu, C. Deng, Z. Xiao, J. Li, Y. Q. Wang, S. Zeng, Shouman Wang, Wenjun Yi Frontiers in Pharmacology.2021;[Epub] CrossRef
Updates on Molecular Targeted Therapies for Intraparenchymal CNS Metastases Akanksha Sharma, Lauren Singer, Priya Kumthekar Cancers.2021; 14(1): 17. CrossRef
Purpose
This study aimed to investigate the potential systemic antitumor effects of stereotactic ablative radiotherapy (SABR) and apatinib (a novel vascular endothelial growth factor receptor 2 inhibitor) via reversing the immunosuppressive tumor microenvironment for lung carcinoma.
Materials and Methods
Lewis lung cancer cells were injected into C57BL/6 mice in the left hindlimb (primary tumor; irradiated) and in the right flank (secondary tumor; nonirradiated). When both tumors grew to the touchable size, mice were randomly divided into eight treatment groups. These groups received normal saline or three distinct doses of apatinib (50 mg/kg, 150 mg/kg, and 200 mg/kg) daily for 7 days, in combination with a single dose of 15 Gy radiotherapy or not to the primary tumor. The further tumor growth/regression of mice were followed and observed.
Results
For the single 15 Gy modality, tumor growth delay could only be observed at the primary tumor. When combining SABR and apatinib 200 mg/kg, significant retardation of both primary and secondary tumor growth could be observed, indicated an abscopal effect was induced. Mechanism analysis suggested that programmed death-ligand 1 expression increased with SABR was counteract by additional apatinib therapy. Furthermore, when apatinib was combined with SABR, the composition of immune cells could be changed. More importantly, this two-pronged approach evoked tumor antigen–specific immune responses and the mice were resistant to another tumor rechallenge, finally, long-term survival was improved.
Conclusion
Our results suggested that the tumor microenvironment could be managed with apatinib, which was effective in eliciting an abscopal effect induced by SABR.
Citations
Citations to this article as recorded by
Comparison of Efficacy and Safety of Different Second-line Therapies for Patients With Advanced Thymic Carcinoma K. Shao, Y. Hao, M. Xu, Z. Shi, G. Lin, C. Xu, Y. Zhang, Z. Song Clinical Oncology.2024; 36(11): 710. CrossRef
Immune effect and prognosis of transcatheter arterial chemoembolization and tyrosine kinase inhibitors therapy in patients with hepatocellular carcinoma Yuan Guo, Ru-Chun Li, Wei-Li Xia, Xiong Yang, Wen-Bo Zhu, Fang-Ting Li, Hong-Tao Hu, Hai-Liang Li World Journal of Gastrointestinal Oncology.2024; 16(7): 3256. CrossRef
A disintegrin and metalloproteinase domain 10 expression inhibition by the small molecules adenosine, cordycepin and N6, N6-dimethyladenosine and immune regulation in malignant cancers Wenqian Zhang, Jiewen Fu, Jiaman Du, Xiaoyan Liu, Jingliang Cheng, Chunli Wei, Youhua Xu, Junjiang Fu Frontiers in Immunology.2024;[Epub] CrossRef
Antiangiogenic Treatment Facilitates the Abscopal Effect of Radiation Therapy Combined With Anti-PD-1 in Hepatocellular Carcinoma Hailong Sheng, Yongyi Luo, Liting Zhong, Zhiyi Wang, Zhichao Sun, Xinna Gao, Xinrong He, Zhenru Zhu, Dehua Wu, Jingyuan Sun, Chuanhui Cao International Journal of Radiation Oncology*Biology*Physics.2024;[Epub] CrossRef
Low‐ dose Apatinib promotes vascular normalization and hypoxia reduction and sensitizes radiotherapy in lung cancer Shanshan Jiang, Yue Zhou, Liqing Zou, Li Chu, Xiao Chu, Jianjiao Ni, Yida Li, Tiantian Guo, Xi Yang, Zhengfei Zhu Cancer Medicine.2023; 12(4): 4434. CrossRef
Local Destruction of Tumors and Systemic Immune Effects Karl-Göran Tranberg Frontiers in Oncology.2021;[Epub] CrossRef
A novel role for apatinib in enhancing radiosensitivity in non-small cell lung cancer cells by suppressing the AKT and ERK pathways Lin Li, Yuexian Li, Huawei Zou PeerJ.2021; 9: e12356. CrossRef
Purpose
BioPATH is a non-interventional study evaluating the relationship of molecular biomarkers (PTEN deletion/downregulation, PIK3CA mutation, truncated HER2 receptor [p95HER2], and tumor HER2 mRNA levels) to treatment responses in Asian patients with HER2+ advanced breast cancer treated with lapatinib and other HER2-targeted agents. Materials and Methods
Female Asian HER2+ breast cancer patients (n=154) who were candidates for lapatinib-based treatment following metastasis and having an available primary tumor biopsy specimen were included. The primary endpoint was progression-free survival (PFS). Secondary endpoints were response rate, overall survival on lapatinib, correlation between biomarker status and PFS for any previous trastuzumab-based treatment, and conversion/conservation rates of the biomarker status between tissue samples collected at primary diagnosis and at recurrence/metastasis. Potential relationships between tumor mRNA levels of HER2 and response to lapatinib-based therapy were also explored.
Results
p95HER2, PTEN deletion/downregulation, and PIK3CA mutation did not demonstrate any significant co-occurrence pattern and were not predictive of clinical outcomes on either lapatinib-based treatment or any previous trastuzumab-based therapy in the metastatic setting. Proportions of tumors positive for p95HER2 expression, PIK3CA mutation, and PTEN deletion/down-regulation at primary diagnosis were 32%, 31.2%, and 56.2%, respectively. Despite limited availability of paired samples, biomarker status patterns were conserved in most samples. HER2 mRNA levels were not predictive of PFS on lapatinib.
Conclusion
The prevalence of p95HER2 expression, PIK3CA mutation, and PTEN deletion/downregulation at primary diagnosis were similar to previous reports. Importantly, no difference was observed in clinical outcome based on the status of these biomarkers, consistent with reports from other studies.
Citations
Citations to this article as recorded by
PIK3CA Mutation is Associated with Poor Response to HER2-Targeted Therapy in Breast Cancer Patients Ju Won Kim, Ah Reum Lim, Ji Young You, Jung Hyun Lee, Sung Eun Song, Nam Kwon Lee, Seung Pil Jung, Kyu Ran Cho, Cheol Yong Kim, Kyong Hwa Park Cancer Research and Treatment.2023; 55(2): 531. CrossRef
Discordance of PIK3CA mutational status between primary and metastatic breast cancer: a systematic review and meta-analysis Justus Rosin, Ella Svegrup, Antonios Valachis, Ioannis Zerdes Breast Cancer Research and Treatment.2023; 201(2): 161. CrossRef
Association of PIK3CA mutation with outcomes in HER2-positive breast cancer treated with anti-HER2 therapy: A meta-analysis and bioinformatic analysis of TCGA‑BRCA data Haizhu Chen, Xingbin Hu, Daquan Wang, Ying Wang, Yunfang Yu, Herui Yao Translational Oncology.2023; 37: 101738. CrossRef
Comparison of PIK3CA Mutation Prevalence in Breast Cancer Across Predicted Ancestry Populations Jessica W. Chen, Karthikeyan Murugesan, Justin Y. Newberg, Ethan S. Sokol, Heidi M. Savage, Thomas J. Stout, Sophia L. Maund, Katherine E. Hutchinson JCO Precision Oncology.2022;[Epub] CrossRef
Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments Ugo Testa, Germana Castelli, Elvira Pelosi Medical Sciences.2020; 8(1): 18. CrossRef
Purpose
Lapatinib is a candidate drug for treatment of trastuzumab-resistant, human epidermal growth factor receptor 2 (HER2)–positive gastric cancer (GC). Unfortunately, lapatinib resistance renders this drug ineffective. The present study investigated the implication of forkhead box O1 (FOXO1) signaling in the acquired lapatinib resistance in HER2-positive GC cells.
Materials and Methods
Lapatinib-resistant GC cell lines (SNU-216 LR2-8) were generated in vitro by chronic exposure of lapatinib-sensitive, HER2-positive SNU-216 cells to lapatinib. SNU-216 LR cells with FOXO1 overexpression were generated by stable transfection of a constitutively active FOXO1 mutant (FOXO1A3). HER2 and MET in SNU-216 LR cells were downregulated using RNA interference. The sensitivity of GC cells to lapatinib and/or cisplatin was determined by crystal violet assay. In addition, Western blot analysis, luciferase reporter assay and reverse transcription–polymerase chain reaction were performed.
Results
SNU-216 LR cells showed upregulations of HER2 and MET, but downregulation of FOXO1 compared to parental SNU-216 cells. FOXO1 overexpression in SNU-216 LR cells significantly suppressed resistance to lapatinib and/or cisplatin. In addition, FOXO1 negatively controlled HER2 and MET at the transcriptional level and was negatively controlled by these molecules at the post-transcriptional level. A positive crosstalk was shown between HER2 and MET, each of which increased resistance to lapatinib and/or cisplatin.
Conclusion
FOXO1 serves as an important linker between HER2 and MET signaling pathways through negative crosstalks and is a key regulator of the acquired lapatinib resistance in HER2-positive GC cells. These findings provide a rationale for establishing a novel treatment strategy to overcome lapatinib resistance in a subtype of GC patients.
Citations
Citations to this article as recorded by
The FOXO1/G6PC axis promotes gastric cancer progression and mediates 5‐fluorouracil resistance by targeting the PI3K/AKT/mTOR signaling pathway Anna Han, Taorui Liu, Pan Du, Mengying Wang, Jiajing Liu, Liyan Chen Molecular Carcinogenesis.2024; 63(4): 688. CrossRef
Characterization of MET Alterations in 37 Gastroesophageal Cancer Cell Lines for MET-Targeted Therapy Jin-Soo Kim, Mi Young Kim, Sungyoul Hong International Journal of Molecular Sciences.2024; 25(11): 5975. CrossRef
HER2-targeted therapies beyond breast cancer — an update Jeesun Yoon, Do-Youn Oh Nature Reviews Clinical Oncology.2024; 21(9): 675. CrossRef
Resistance to Anti-HER2 Therapies in Gastrointestinal Malignancies Christiana Mo, Michelle Sterpi, Hyein Jeon, Fernand Bteich Cancers.2024; 16(16): 2854. CrossRef
The novel BCL-2/BCL-XL inhibitor APG-1252-mediated cleavage of GSDME enhances the antitumor efficacy of HER2-targeted therapy in HER2-positive gastric cancer Qiu-yun Luo, Jing Yang, Tian Di, Zeng-fei Xia, Lin Zhang, Wen-tao Pan, Shan Shi, Li-qiong Yang, Jian Sun, Miao-zhen Qiu, Da-jun Yang Acta Pharmacologica Sinica.2024;[Epub] CrossRef
FoxO1 Deficiency in Monocytic Myeloid‐Derived Suppressor Cells Exacerbates B Cell Dysfunction in Systemic Lupus Erythematosus Liping Tan, Wei Kong, Kangxing Zhou, Shuangan Wang, Jun Liang, Yayi Hou, Huan Dou Arthritis & Rheumatology.2024;[Epub] CrossRef
Targeted and Immunotherapy Approaches in HER2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma: A New Era Maluki Radford, Hassan Abushukair, Stijn Hentzen, Ludimila Cavalcante, Anwaar Saeed Journal of Immunotherapy and Precision Oncology.2023; 6(3): 150. CrossRef
Resistance mechanisms to HER2-targeted therapy in gastroesophageal adenocarcinoma: A systematic review Dionne Blangé, Charlotte I. Stroes, Sarah Derks, Maarten F. Bijlsma, Hanneke W.M. van Laarhoven Cancer Treatment Reviews.2022; 108: 102418. CrossRef
The FOXO family of transcription factors: key molecular players in gastric cancer Ying Liu, Xiang Ao, Yi Jia, Xiaoge Li, Yu Wang, Jianxun Wang Journal of Molecular Medicine.2022; 100(7): 997. CrossRef
VGLL1 phosphorylation and activation promotes gastric cancer malignancy via TGF-β/ERK/RSK2 signaling Joo-Young Im, Da-Mi Kim, Hyunkyung Park, Mi-Jung Kang, Da-Yoon Kim, Kwan Young Chang, Bo-Kyung Kim, Misun Won Biochimica et Biophysica Acta (BBA) - Molecular Cell Research.2021; 1868(1): 118892. CrossRef
The efficacy and safety of onartuzumab in patients with solid cancers: A meta-analysis of randomized trials BumJun Kim, Dalyong Kim, JungHan Kim, HyeongSu Kim, HyunJoo Jang Indian Journal of Cancer.2021; 58(2): 232. CrossRef
HER2-targeted therapies in gastric cancer Yinxing Zhu, Xuedan Zhu, Xiaowei Wei, Cuiju Tang, Wenwen Zhang Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2021; 1876(1): 188549. CrossRef
Current therapeutic options for gastric adenocarcinoma C.R. Akshatha, Smitha Bhat, R. Sindhu, Dharini Shashank, Sarana Rose Sommano, Wanaporn Tapingkae, Ratchadawan Cheewangkoon, Shashanka K. Prasad Saudi Journal of Biological Sciences.2021; 28(9): 5371. CrossRef
Diverse roles of FOXO family members in gastric cancer Yu-Han Chen, Chun-Lan Li, Wen-Jia Chen, Jing Liu, Hua-Tao Wu World Journal of Gastrointestinal Oncology.2021; 13(10): 1367. CrossRef
Overcoming resistance to targeted therapy using MET inhibitors in solid cancers: evidence from preclinical and clinical studies Nehad M. Ayoub, Dalia R. Ibrahim, Amer E. Alkhalifa Medical Oncology.2021;[Epub] CrossRef
Fertility preservation in women with ovarian cancer: Finding new pathways: A case-control study Ali Khodadadian, Yasser Varghaiyan, Emad Babakhanzadeh, Iraj Alipourfard, Saeed Haghi-Daredeh, Amin Ghobadi, Mohsen Hemmati-Dinarvand, Mehrdad Talebi, Nasrin Ghasemi International Journal of Reproductive BioMedicine (IJRM).2021; 19(2): 157. CrossRef
Caveolin-1 Promotes Chemoresistance of Gastric Cancer Cells to Cisplatin by Activating WNT/β-Catenin Pathway Xi Wang, Bin Lu, Chunyan Dai, Yufei Fu, Ke Hao, Bing Zhao, Zhe Chen, Li Fu Frontiers in Oncology.2020;[Epub] CrossRef
Machine Learning-Guided Prediction of Antigen-Reactive In Silico Clonotypes Based on Changes in Clonal Abundance through Bio-Panning Duck Kyun Yoo, Seung Ryul Lee, Yushin Jung, Haejun Han, Hwa Kyoung Lee, Jerome Han, Soohyun Kim, Jisu Chae, Taehoon Ryu, Junho Chung Biomolecules.2020; 10(3): 421. CrossRef
FOXO transcription factor family in cancer and metastasis Yannasittha Jiramongkol, Eric W.-F. Lam Cancer and Metastasis Reviews.2020; 39(3): 681. CrossRef
In vitro and in vivo Anti-Tumor Effects of Pan-HER Inhibitor Varlitinib on Cholangiocarcinoma Cell Lines
MiR-27a promotes EMT in ovarian cancer through active Wnt/ Li-Ya Zhang, Yuan Chen, Jue Jia, Xi Zhu, Yan He, Li-Ming Wu Cancer Biomarkers.2019; 24(1): 31. CrossRef
Role of FoxO Proteins in Cellular Response to Antitumor Agents Giovanni Luca Beretta, Cristina Corno, Nadia Zaffaroni, Paola Perego Cancers.2019; 11(1): 90. CrossRef
Members of FOX family could be drug targets of cancers Jinhua Wang, Wan Li, Ying Zhao, De Kang, Weiqi Fu, Xiangjin Zheng, Xiaocong Pang, Guanhua Du Pharmacology & Therapeutics.2018; 181: 183. CrossRef
FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models Cristina Corno, Simone Stucchi, Michelandrea De Cesare, Nives Carenini, Serena Stamatakos, Emilio Ciusani, Lucia Minoli, Eugenio Scanziani, Christian Argueta, Yosef Landesman, Nadia Zaffaroni, Laura Gatti, Paola Perego Biochemical Pharmacology.2018; 147: 93. CrossRef
Nuclear division cycle 80 promotes malignant progression and predicts clinical outcome in colorectal cancer Xuebing Yan, Linsheng Huang, Liguo Liu, Huanlong Qin, Zhenshun Song Cancer Medicine.2018;[Epub] CrossRef
Systems analysis of key genes and pathways in the progression of hepatocellular carcinoma Yu-Kui Shang, Fanni Li, Yi Zhang, Ze-Kun Liu, Zi-Ling Wang, Huijie Bian, Zhi-Nan Chen Medicine.2018; 97(23): e10892. CrossRef
The Dominant Role of Forkhead Box Proteins in Cancer Duc-Hiep Bach, Nguyen Phuoc Long, Thi-Thu-Trang Luu, Nguyen Hoang Anh, Sung Won Kwon, Sang Kook Lee International Journal of Molecular Sciences.2018; 19(10): 3279. CrossRef
HSP90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells Kang-Seo Park, Yong Sang Hong, Junyoung Choi, Shinkyo Yoon, Jihoon Kang, Deokhoon Kim, Kang-Pa Lee, Hyeon-Su Im, Chang Hoon Lee, Seyoung Seo, Sang-We Kim, Dae Ho Lee, Sook Ryun Park BMB Reports.2018; 51(12): 660. CrossRef
FOXO1 reduces tumorsphere formation capacity and has crosstalk with LGR5 signaling in gastric cancer cells Yiseul Choi, Jinju Park, Young San Ko, Younghoon Kim, Jung-Soo Pyo, Bo Gun Jang, Min A Kim, Jae-Seon Lee, Mee Soo Chang, Byung Lan Lee Biochemical and Biophysical Research Communication.2017; 493(3): 1349. CrossRef
Trifluoperazine Activates FOXO1-Related Signals to Inhibit Tumor Growth in Hepatocellular Carcinoma Jingwen Jiang, Zhongxi Huang, Xuewu Chen, Rongcheng Luo, Hongbin Cai, Hairu Wang, Hui Zhang, Tao Sun, Yunfang Zhang DNA and Cell Biology.2017; 36(10): 813. CrossRef